How to Find a GLP-1 Prescriber Near You: The 2026 Patient Guide

There are four legitimate ways to get a GLP-1 prescription in 2026: an in-person primary care or obesity-medicine specialist visit, a licensed telehealth platform, NovoCare Pharmacy direct (Wegovy), or LillyDirect Self Pay (Zepbound and Foundayo). Any “no-prescription” GLP-1 source is illegal and likely fraudulent. GLP-1 receptor agonists are prescription-only injectable or oral medications in the United States — semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda, Victoza), and orforglipron (Foundayo) are all Schedule nothing but Rx-only. A licensed clinician must take a medical history, document a qualifying indication (BMI ≥30, or BMI ≥27 with a weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or cardiovascular disease for the chronic-weight-management labels), and write the prescription before any pharmacy can legally dispense the drug. This guide walks you through the four real pathways — what each one costs, how to verify it is legitimate, when it is the right choice for you, and the red flags that mean you are looking at a grey-market or counterfeit source.

At a glance: the four pathways

• (1) In-person primary care, endocrinology, or obesity-medicine specialist. The default route if you have commercial insurance, Medicare, or Medicaid (state-dependent). Your PCP can prescribe Wegovy, Zepbound, Saxenda, Foundayo, Mounjaro (for diabetes), and Ozempic (for diabetes) the same as any other Rx. Expect a prior-authorization step from most commercial payers.
• (2) Telehealth platforms. Ro, Hims, Mochi Health, Henry Meds, Found, WeightWatchers Clinic, LillyDirect (the partnered-telehealth side), and many others. Cash-pay monthly fees commonly $99–$349 for branded GLP-1s plus medication cost; compounded semaglutide programs $199–$399/month all-in. Verify accreditation via LegitScript^[4] and NABP^[5] before submitting payment.
• (3) NovoCare Pharmacy direct (Wegovy only). Novo Nordisk’s direct cash-pay pathway. Skip insurance entirely. ~$499/month baseline (refreshed mid-2026 to a $399 HD pen tier plus a new $149 oral pill tier per the manufacturer site^[9]). Requires a valid prescription from any licensed US clinician.
• (4) LillyDirect Self Pay Pharmacy (Zepbound and Foundayo). Eli Lilly’s direct cash-pay pathway. Zepbound single-dose vials at $349–$499/month (dose-dependent), Foundayo (orforglipron) oral once-daily at $149/month^[10]. Also requires a valid Rx from any licensed US clinician.
• Compounded GLP-1s are a separate regulatory category we treat as a fifth, qualified pathway. The FDA shortage-list enforcement-discretion grace period for compounded semaglutide ended in early 2025 after the brand shortage resolved^[6]; the compounded-tirzepatide grace period ended late 2024. 503A pharmacies may still legally compound for patient-specific medical necessity (e.g., allergy-driven excipient swap), but the routine mass-compounded weight-loss program is no longer shortage-exempt. The legal landscape is unsettled.
• No-prescription, no-medical-screening sources are illegal in all 50 states. “Research peptide” vendors, international mail-order pharmacies that ship without a US Rx, social-media DMs offering vials, and any seller asking for crypto or wire-only payment are operating outside the US drug supply chain. Counterfeit semaglutide has been identified in the US in 2023–2025 per FDA warning letters.
• The honest cost reality. With commercial insurance + prior authorization approval: $25–$200/month copay. Without insurance: $149/month (Foundayo oral) to $1,300+/month (retail Wegovy/Zepbound before manufacturer programs). Telehealth-bundled compounded options $199–$399/month with the regulatory caveat above.

Option 1: Your primary care or obesity-medicine specialist

The American Medical Association formally recognized obesity as a chronic disease in 2013 (AMA Policy H-440.842^[7]), which means your primary-care clinician can — and increasingly does — prescribe FDA-approved obesity pharmacotherapy directly. If you have an established relationship with a PCP, this is almost always the right place to start. Three reasons:

(1) Coverage navigation is easier with an in-network clinician. Commercial payers (Aetna, Cigna, UHC, BCBS plans, Anthem, Humana) require prior authorization for chronic-weight-management GLP-1s with documentation of BMI, comorbidities, prior weight-loss attempts, and sometimes a structured-lifestyle-program enrollment. Your PCP’s office handles the PA paperwork through the payer’s standard workflow; a one-off telehealth prescriber typically does not have the same chart history to support the PA narrative and will often defer to a cash-pay program instead.

(2) Comorbidity screening is the load-bearing clinical step. Before starting a GLP-1, a clinician should screen for personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN 2), pancreatitis, severe gastroparesis, gallbladder disease, pregnancy planning, and diabetic-retinopathy stability if you have type 2 diabetes. These are the FDA-label contraindications and warnings. An in-person visit with someone who has your chart is the most reliable way to get this right.

(3) Side-effect management and titration are clinically nontrivial. Nausea, vomiting, gallbladder symptoms, dehydration, and rare bowel-obstruction signals all need a clinician who can be reached, will order imaging or labs as needed, and can pause or de-escalate dose. A continuous primary-care relationship beats a quarterly telehealth check-in for this.

Who is qualified to prescribe in person: any licensed MD, DO, NP, or PA practicing in your state. Endocrinologists and obesity-medicine specialists (American Board of Obesity Medicine diplomates) are the subspecialty equivalents — useful if your case is complicated by diabetes, lipid disorders, polycystic ovary syndrome, bariatric-surgery history, or prior intolerance to a GLP-1. Find an obesity-medicine specialist via the Obesity Medicine Association directory or the American Board of Obesity Medicine’s diplomate search. Coverage: depends entirely on your plan; check the BCBS / Aetna / UHC / Cigna formulary for your specific employer group before the visit, because Wegovy and Zepbound are not universally covered for weight loss even on plans that cover them for type 2 diabetes.

Cost in this pathway: typically a normal copay ($20–$60) for the office visit. The medication cost depends on your plan’s formulary placement — commonly $25–$200/month copay if covered, full retail ($1,000–$1,300+/month) if not. The Wegovy and Zepbound manufacturer copay-savings cards can reduce commercially insured cost to $0–$25/month for many patients; Saxenda and Foundayo have their own savings programs.

Medicare and Medicaid reality. Medicare Part D historically did not cover medications “for the treatment of obesity,” but the CMS March 2024 memorandum extended Part D coverage to Wegovy when prescribed for established cardiovascular disease in overweight or obese adults^[8] — a meaningful expansion that does NOT cover Wegovy for obesity alone. State Medicaid coverage for GLP-1s for chronic weight management varies wildly — see our provider directory for the state-specific Medicaid pathway articles.

Option 2: Telehealth platforms (the realistic costs and accreditation flags)

Telehealth platforms are the second most common access pathway in 2026. They legitimately serve patients without a current PCP, patients whose PCP will not prescribe GLP-1s for obesity, patients in employer plans that exclude GLP-1 weight-loss coverage, and patients who prefer to cash-pay for privacy or simplicity. The operational model is similar across platforms: you fill out an intake (height, weight, medical history, BMI, comorbidities), you submit photos and sometimes lab work, a licensed clinician (NP, PA, or MD) reviews your file within 24–72 hours, and if you qualify they write the prescription that gets routed either to a partnered 503A compounding pharmacy or to a retail pharmacy for a branded fill.

The legitimate platforms in 2026 we monitor in our provider directory include Ro, Hims/Hers, Mochi Health, Henry Meds, Found, WeightWatchers Clinic, LillyDirect (telehealth side via Form/9amHealth/Cove), Sequence, Calibrate, Embla, Eden, EllieMD, and roughly 220 more vetted entries. The accreditation flags that distinguish a legitimate platform from a grey-market vendor:

• LegitScript Healthcare Merchant Certification. LegitScript^[4] is the industry-standard third-party certifier for telehealth and online pharmacies. Browser, payment processors, and Google’s healthcare-ads program all require LegitScript certification. Search the platform name directly at legitscript.com/searchresults. Absence is not always disqualifying (some legitimate platforms delegate to a partnered LegitScript-certified pharmacy rather than holding the cert themselves), but presence is a strong positive signal.
• NABP .pharmacy or NABP-accredited partnered pharmacy. The National Association of Boards of Pharmacy^[5] runs the .pharmacy Verified Websites Program. A platform that fills through an NABP-accredited pharmacy meets US-licensed-pharmacy standards. Look for the verification seal in the footer, then verify the seal by clicking through to NABP’s registry rather than trusting the image alone.
• State pharmacy board registration of the partnered pharmacy. Every legitimate dispensing pharmacy is registered with the pharmacy board of the state it ships from AND of the state it ships to. You can verify both via your state pharmacy board’s online lookup. Compounding (503A) pharmacies must also be registered with the state board.
• Clinician licensure verification. The platform should publish — or be able to disclose on request — the prescribing clinician’s name, license number, and state of licensure. Verify the license is active and in your state via your state medical or nursing board lookup. A clinician must hold an active license in the state where YOU (the patient) are located at the time of the visit.
• HIPAA-compliant intake. Real platforms encrypt your medical history, use authenticated patient portals, and publish a Notice of Privacy Practices. A vendor that accepts your medical history via SMS, unencrypted email, or Telegram is not HIPAA-compliant.
• FDA-approved branded GLP-1 access (preferred) or transparent 503A compounding pharmacy disclosure (acceptable with caveats). The platform should clearly state whether you are receiving FDA- approved branded medication (Wegovy, Zepbound, Saxenda, Foundayo, Mounjaro for diabetes, Ozempic for diabetes) or a compounded analog. If compounded: the platform should disclose the partnered 503A pharmacy by name and that pharmacy’s state of registration. The FDA grace periods^[6] for routine compounding of semaglutide and tirzepatide have ended; ongoing compounded supply must be justified by patient-specific medical necessity (allergy, dose customization).

Cost on telehealth: branded GLP-1s through telehealth commonly run $99–$349/month for the platform consultation fee plus the manufacturer-set medication price (~$499/month NovoCare Wegovy; $349–$499/month LillyDirect Zepbound vials; $149/month LillyDirect Foundayo). Compounded semaglutide programs commonly run $199–$399/month all-in (consult + medication bundled). Some platforms quote “starting from $99” based on a single dose tier and increase substantially at higher doses — read the full dose ladder pricing before signing up. The truly cheapest compounded options are documented in our cheapest compounded semaglutide research review.

Option 3: Direct from manufacturer (NovoCare Pharmacy + LillyDirect)

The manufacturer-direct cash-pay programs are the cleanest and most regulatorily-stable cash route — you are buying the FDA-approved branded drug from the manufacturer’s own pharmacy at a set monthly cash-pay price, no insurance step involved. The two programs that matter:

NovoCare Pharmacy (Novo Nordisk). Cash-pay Wegovy direct from Novo Nordisk^[9]. Baseline was $499/month for the prefilled-pen formulation; refreshed in mid-2026 to a $399/month HD pen tier and a new $149/month oral pill tier (semaglutide oral for chronic weight management). You still need a prescription from a licensed US clinician — NovoCare does not have a partnered telehealth prescribing arm in the same way LillyDirect does. The Rx can come from your PCP, an obesity-medicine specialist, or a separate telehealth platform; NovoCare just dispenses. Best fit: you already have a clinician willing to prescribe Wegovy but your insurance does not cover it, you want a predictable cash-pay price, and you want the FDA-approved branded product rather than a compounded analog.

LillyDirect Self Pay Pharmacy (Eli Lilly). Cash-pay Zepbound vials and Foundayo (orforglipron) oral direct from Eli Lilly^[10]. Zepbound single-dose vials at $349–$499/month depending on dose; Foundayo once-daily oral tablets at $149/month. LillyDirect has both a self-pay-only pharmacy (you supply the Rx) and a partnered telehealth platform (Form Health, 9amHealth, Cove, and others) that can prescribe and route through LillyDirect. Best fit: you want FDA-approved branded tirzepatide or orforglipron at a predictable cash-pay price, you do not need or have GLP-1 weight-loss insurance coverage, and you want the easiest legal cash-pay pathway.

Both programs are firmly on the legitimate side of every accreditation question above: NovoCare and LillyDirect are owned and operated by the FDA-approved manufacturer of the medication. There is no LegitScript step needed — the manufacturer is the regulated entity. Your only verification step is making sure you are on the actual novocare.com / lillydirect.lilly.com domain, not a lookalike phishing site. Both pharmacies are NABP- registered.

Option 4: Compounded GLP-1s — the legal status is unsettled

Compounded semaglutide and compounded tirzepatide were widely available 2022–2024 under the FDA shortage-list enforcement-discretion grace period, which allowed 503A compounding pharmacies to prepare patient-specific formulations of drugs the brand manufacturer could not supply in sufficient quantity. That grace period ended: compounded tirzepatide in October 2024 after the Lilly tirzepatide shortage resolved, and compounded semaglutide in early 2025 after the Novo Nordisk shortage resolved^[6]. The current legal status:

• 503A compounding pharmacies can still legally prepare patient-specific compounded formulations IF there is a documented medical reason the FDA-approved branded product cannot be used — for example, a patient with a documented allergy to an excipient (preservative, buffer), a dose the manufacturer does not offer (an off-label intermediate-dose), or a specific clinical-monitoring rationale. This is “patient-specific compounding” in the regulatory sense and remains legal under section 503A.
• Routine, large-batch, weight-loss-program compounding is no longer shortage-exempt. Many telehealth platforms have transitioned their compounded-GLP-1 programs to a “medically necessary” documentation pattern — but the FDA has issued warning letters to some 503A pharmacies for what it characterizes as systemic compounding rather than truly patient-specific medical-necessity compounding. The legal landscape is unsettled and actively litigated. If you choose this pathway, choose a platform that transparently discloses the partnered 503A pharmacy, the clinical-justification framework, and the testing/QA protocols.
• 503B outsourcing-facility compounding is a separate, more regulated category. 503B facilities can prepare larger batches without patient-specific prescriptions but are subject to full FDA cGMP inspection. Some hospital pharmacies and larger compounding operations are 503B-registered. Most retail-telehealth compounded GLP-1 programs are NOT sourced from 503B facilities.
• Avoid “research peptides” and international mail-order vendors. Vendors selling unapproved semaglutide or tirzepatide marketed “for research only,” or shipping unregistered product from China, India, or Eastern European mail-order facilities, are operating outside the US regulatory framework. Counterfeit semaglutide containing wrong active ingredient, no active ingredient, or contaminated formulation has been identified in US-bound shipments per FDA enforcement^[6].

For a deeper treatment of compounded options and the pricing/quality landscape, see our cheapest compounded semaglutide review and the broader Wegovy alternatives 2026 guide. The full vetted directory of telehealth platforms and 503A partnered pharmacies is at our pharmacy directory.

How to verify a telehealth platform is legitimate

Three-step verification before you submit payment to any telehealth GLP-1 platform:

(1) LegitScript lookup. Go to legitscript.com and search the platform name. A certified telehealth merchant or certified internet pharmacy returns a green-status profile with the certification scope (telehealth services, pharmacy, addiction treatment, etc.) and the certification date. If the platform is not listed, look for whether the partnered dispensing pharmacy is listed separately (often legitimate platforms operate as a clinical front-end with a separately LegitScript-certified pharmacy back-end). If neither the platform nor any partnered pharmacy is LegitScript-certified, that is the strongest single red flag.

(2) NABP verification of the partnered pharmacy. Find the pharmacy name on the platform’s site (usually in the FAQ, terms, or privacy policy). Then go to nabp.pharmacy and search the pharmacy under the .pharmacy Verified Websites Program or under accreditations and inspections. NABP also maintains a “Not Recommended” list of sites operating outside US regulatory framework — a useful exclusion check.

(3) State pharmacy board AND state medical board lookup. The dispensing pharmacy must be registered in your state to ship to you (or registered in the state it ships from AND have a non-resident pharmacy license in your state). The prescribing clinician must hold an active license in your state at the time of the prescription. Both lookups are free and public on the relevant state-board website. If either license is inactive, expired, or in a different state from yours, that is a hard stop.

Optional additional checks: Better Business Bureau rating (not perfect but adds a behavioral signal), legitimate billing descriptor (the charge on your card should clearly identify the platform — a generic “health services” descriptor is suspicious), published clinical advisory board with named clinicians who can be verified independently, transparent prescribing-clinician roster.

Red flags: what “no prescription required” actually means

Every GLP-1 receptor agonist sold legally in the United States is a prescription-only medication. There is no FDA-approved over-the-counter semaglutide, tirzepatide, liraglutide, or orforglipron. Any source advertising “no prescription needed,” “skip the doctor visit,” or “research peptide” is selling either (a) an illegal, unapproved drug product, (b) a counterfeit drug, (c) a non-medication oral supplement misrepresented as a GLP-1 (see our GLP-1 patches evidence review and GLP-1 medication list reference for the legitimate-drug catalog versus the supplement- and-patch scam category), or (d) a payment-only scam that does not ship product at all. Specific red flags:

• “Research peptide,” “not for human consumption,” “for laboratory use only” framing combined with weight-loss marketing on the same site. This is a legal-shield tactic, not a product category. Selling unapproved drug ingredients framed for “research” and then marketing the same product as weight-loss treatment is illegal and the FDA has issued multiple warning letters.
• International mail-order pharmacies shipping without a US Rx. Even legitimate Canadian mail-order pharmacies require a US-equivalent prescription. Vendors shipping from Mexico, India, China, Russia, or the UAE without an Rx are outside US regulatory framework entirely — counterfeit rate is high, sterility is not assured, and the product may have wrong active ingredient or contain contaminants.
• Crypto, wire-transfer, or Zelle-only payment. Legitimate US pharmacies accept credit cards through chargeback-eligible processors. A vendor requiring Bitcoin, Ethereum, USDT, or irreversible Zelle/wire payment is deliberately choosing payment methods that prevent fraud chargeback — the strongest behavioral indicator of a fraudulent operation.
• Social-media DMs and Telegram channels selling vials. No legitimate US pharmacy sells prescription medication via Instagram, TikTok, Facebook Marketplace, or Telegram. Period.
• Lookalike domains. Phishing sites imitating NovoCare, LillyDirect, Ro, Hims, etc. with slightly misspelled URLs or different TLDs (novocare-pharmacy.shop, lillydirect-savings.us, ro-glp1.co). Verify the exact root domain matches the manufacturer or platform’s published URL.
• Vials without manufacturer batch identification. Legitimate Wegovy and Zepbound ship with manufacturer NDC numbers, lot numbers, expiration dates, and patient leaflets. Compounded GLP-1s from licensed 503A pharmacies ship with the compounding pharmacy’s identification, lot number, beyond-use date (BUD), and a USP-compliant label. An unlabeled vial, a vial with handwritten dosing, or a vial in a generic plastic baggie is not a legally compounded or manufactured product.

If you have already paid a vendor that fails one or more of these checks: stop further payments immediately, dispute the charge with your card issuer if within the chargeback window, report the vendor to the FDA MedWatch program, and report to your state attorney general’s consumer protection division. Do not inject any product you cannot verify.

Comparing costs across the four options in 2026

Honest 2026 cost ranges, with the meaningful asterisks:

• Primary care + commercial insurance with PA approval: $20–$60 office-visit copay + $25–$200/month medication copay (Wegovy, Zepbound, Saxenda, Foundayo for chronic weight management; Ozempic and Mounjaro for type 2 diabetes). The Wegovy and Zepbound copay-savings cards can drop commercially insured cost to $0–$25/month for many patients.
• Primary care + Medicare Part D (CVD pathway only): Wegovy under the cardiovascular-disease indication^[8] — typical Part D copay tier 4–5 depending on plan, commonly $50–$200/ month after deductible. Part D does NOT cover Wegovy for obesity without established CVD. Foundayo, Zepbound, Saxenda are NOT covered under Part D for chronic weight management as of 2026.
• Primary care + state Medicaid: highly variable. North Carolina, California, Pennsylvania, Virginia, Massachusetts, Michigan, Minnesota, Oregon, Connecticut, Rhode Island, Mississippi, and New Mexico cover at least one GLP-1 for chronic weight management under their Medicaid programs as of 2026 — the others largely do not. Check our provider directory for the state-specific Medicaid pathway article.
• Telehealth + cash-pay branded: $99–$349/month consultation + the manufacturer self-pay medication price ($149/month Foundayo; $349–$499/month NovoCare Wegovy or LillyDirect Zepbound). All-in: roughly $250–$850/month for FDA-approved branded medication via telehealth.
• Telehealth + compounded semaglutide or tirzepatide: $199–$399/month all-in (consult + medication bundled), with the regulatory caveat^[6] that routine mass-compounding is no longer FDA-shortage-exempt and requires patient-specific medical necessity to remain legally compliant.
• NovoCare Pharmacy direct (Wegovy): ~$499/month baseline, $399/month HD pen tier, or $149/month oral pill tier (refreshed mid-2026)^[9]. Requires a valid Rx from any US-licensed clinician.
• LillyDirect Self Pay (Zepbound and Foundayo): Zepbound vials $349–$499/month (dose-dependent); Foundayo oral $149/month^[10]. Requires a valid Rx from any US-licensed clinician.

Worth pricing our GLP-1 savings calculator for the exact dollar comparison given your specific insurance plan, dose, and access pathway.

Magnitude check: what each medication actually does

For context on what you are actually choosing between: the Wilding 2021 STEP-1 trial of semaglutide 2.4 mg weekly^[1] reported a 14.9% reduction in body weight at 68 weeks. The Jastreboff 2022 SURMOUNT-1 trial of tirzepatide 15 mg weekly^[2] reported a 20.9% reduction in body weight at 72 weeks. The Wharton 2025 ATTAIN-1 trial of orforglipron 17.2 mg once-daily^[3] reported an 11.1% reduction in body weight at 72 weeks — lower than the injectables but the first FDA-approved oral GLP-1 for chronic weight management, removing the needle-and-fridge friction that keeps many patients away from the injectable class entirely. All three magnitudes are pharmacotherapy. Diet-and-exercise alone in matched-population trials typically produces 3–8% body weight reduction.

FAQ

Frequently asked patient questions about finding a GLP-1 prescriber, with concise honest answers. Detailed per-pathway guidance is in the sections above.

Bottom line

• Four legitimate pathways in 2026: in-person primary care or obesity-medicine specialist, accredited telehealth platform, NovoCare Pharmacy direct (Wegovy), LillyDirect Self Pay (Zepbound and Foundayo).
• Compounded semaglutide and tirzepatide are a fifth, regulatorily-unsettled category. The FDA shortage-list grace periods^[6] ended in late 2024 / early 2025; routine mass-compounding is no longer shortage-exempt; patient-specific medical necessity is the remaining legal basis.
• Verify any telehealth platform via three independent checks: LegitScript^[4] certification, NABP partnered-pharmacy verification^[5], and state pharmacy board + state medical board lookup for the dispensing pharmacy and prescribing clinician.
• No GLP-1 is legally available over the counter in the United States. “No prescription required,” “research peptide,” international mail-order without a US Rx, and crypto-or-wire-only vendors are red flags for illegal or counterfeit sources.
• Cost varies from $0–$25/month (commercial insurance + manufacturer copay card) to $149/month (Foundayo oral direct from Lilly) to $1,300+/month (cash retail without a manufacturer program). Use our GLP-1 savings calculator to model your specific case.
• Magnitude check: Foundayo orforglipron oral −11.1% at 72 weeks (ATTAIN-1^[3]), Wegovy semaglutide −14.9% at 68 weeks (STEP-1^[1]), Zepbound tirzepatide −20.9% at 72 weeks (SURMOUNT-1^[2]). Pathway choice does not change pharmacology — the same dose of the same drug works the same way regardless of whether it came through your PCP or a telehealth platform.
• Start with your PCP if you have one. It is the highest-touch, lowest-cost-if-insured pathway, gets the comorbidity screening done correctly, and builds the documentation that supports prior authorization across multiple medications and dose steps over time.

Related research and tools

• WLR provider directory — the full vetted list of telehealth platforms, in-person obesity-medicine practices, and state Medicaid pathway articles. Filter by category, coverage, and confidence level.
• WLR pharmacy directory — vetted NABP-registered and LegitScript- certified pharmacies, including 503A compounding pharmacies with disclosed quality protocols.
• GLP-1 medication list: full reference — the catalog of every FDA-approved GLP-1 receptor agonist with brand, generic, dose, indication, and label-level evidence.
• Wegovy alternatives 2026 guide — the deep treatment of Zepbound, Foundayo, Saxenda, generic liraglutide, and compounded options with head-to-head trial data.
• Cheapest compounded semaglutide in 2026 — pricing landscape across vetted 503A- partnered telehealth programs with the regulatory caveats spelled out.
• GLP-1 patches evidence review — the anti-pattern reference for transdermal, oral-supplement, and over-the-counter products marketed as GLP-1 alternatives. None are legitimate replacements for the prescription medications above.
• GLP-1 savings calculator — model your monthly out-of-pocket cost across the four legitimate pathways given your insurance plan, dose, and medication choice.
• Semaglutide, tirzepatide, Wegovy, Zepbound, and Foundayo — per-drug deep pages with label-level dosing, contraindications, and pharmacology.

Important disclaimer. This article is educational and does not constitute medical advice. GLP-1 receptor agonists are prescription-only medications with FDA-label contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior serious hypersensitivity reaction to the drug or any product component, and pregnancy. Before starting any GLP-1, you should be evaluated by a licensed clinician who reviews your full medical history. The accreditation, pricing, and regulatory status descriptions in this article reflect publicly available information as of 2026-05-23 and may change. Always verify the current accreditation of any telehealth platform or pharmacy at the time you submit payment, and verify that the prescribing clinician holds an active license in your state at the time of the consultation. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-23.

Last verified: 2026-05-23. Next review: every 6 months, or sooner if major regulatory or pricing changes occur (FDA action on compounding, Medicare Part D expansion, manufacturer self-pay price refresh).